Special Issue

Psychiatric Drug Treatment and Drug Addiction

Message from the Guest Editor

According to the *Diagnostic and Statistical Manual of* Mental Disorders (DSM-V), drug addiction is a psychiatric disorder presenting a major public health burden across the world, especially in developed countries. People with drug dependence usually have more psychiatric conditions or are prescribed psychiatric drugs. Nowadays, new treatments for patients to prevent relapses, one of the main problems of drug addiction, are imperative. Also, drugs that improve the quality of life of these patients are necessary. Furthermore, we are currently living in a time with the most people diagnosed with mental issues in history. For these reasons, we are particularly interested in insights into new psychiatric drugs and new treatments for drug addiction for this Special Issue. Research articles and reviews investigating drugs of abuse and psychiatric drugs, commercialized or not (as well as drugs in the clinical trial phase), are also welcome.

Guest Editor

Dr. Javier Navarro-Zaragoza

Department of Pharmacology, Faculty of Medicine, University of Murcia, 30100 Murcia, Spain

Deadline for manuscript submissions

closed (25 August 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/195288

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

